Neuland Laboratories is currently trading at Rs. 1245.00, up by 26.55 points or 2.18% from its previous closing of Rs. 1218.45 on the BSE.
The scrip opened at Rs. 1248.00 and has touched a high and low of Rs. 1299.00 and Rs. 1190.00 respectively. So far 18138 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1680.00 on 05-Apr-2017 and a 52 week low of Rs. 877.15 on 22-Feb-2017.
Last one week high and low of the scrip stood at Rs. 1299.00 and Rs. 1142.75 respectively. The current market cap of the company is Rs. 1088.32 crore.
The promoters holding in the company stood at 51.68%, while Institutions and Non-Institutions held 14.31% and 34.01% respectively.
Neuland Laboratories has received an approval for purchase of a manufacturing facility, comprising of land, buildings, plant, machinery and equipment, owned by Arch Pharmalabs situated at Gaddapotharam, Jinnaram Mandal, Sanga Reddy District, under the provisions of Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest Act, 2002 (SARFAESI) from JM Financial Asset Reconstruction Company (JMFARC) by mutual consent.
The purchase would take place by way of execution of a Sale Certificate by JMFARC in accordance with the provisions of the SARFAESI, upon completion certain Conditions. The board of directors at their meeting held on November 22, 2017, has approved for the same.
Neuland Laboratories manufactures active pharmaceutical ingredients for global pharmaceutical companies and provides end-to-end solutions for the pharmaceutical industry for chemistry-related services.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1619.95 |
| Dr. Reddys Lab | 1315.85 |
| Cipla | 1294.75 |
| Zydus Lifesciences | 927.15 |
| Lupin | 2296.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: